Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.

Autor: Stroh M; Department of Clinical Pharmacology, Genentech South San Francisco, California, USA., Carlile DJ; Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Welwyn, UK., Li CC; Department of Clinical Pharmacology, Genentech South San Francisco, California, USA., Wagg J; Roche Innovation Center Basel Switzerland., Ribba B; Roche Innovation Center Basel Switzerland., Ramanujan S; Department of Preclinical and Translational PKPD, Genentech South San Francisco, CA, USA., Jin J; Department of Clinical Pharmacology, Genentech South San Francisco, California, USA., Xu J; Department of Clinical Pharmacology, Genentech South San Francisco, California, USA., Charoin JE; Roche Innovation Center Basel Switzerland., Xhu ZX; Roche Innovation Center New York New York, USA., Morcos PN; Department of Preclinical and Translational PKPD, Genentech South San Francisco, CA, USA., Davis JD; Department of Clinical Pharmacology, Genentech South San Francisco, California, USA., Phipps A; Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Welwyn, UK.
Jazyk: angličtina
Zdroj: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2015 Sep; Vol. 4 (9), pp. 495-7. Date of Electronic Publication: 2015 Sep 11.
DOI: 10.1002/psp4.12014
Abstrakt: Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT.
Databáze: MEDLINE
Externí odkaz: